The Law Offices of Howard G. Smith Notifies Investors of the Filing of a Securities Class Action on Behalf of ImmunoCellular Therapeutics, Ltd. Investors

BENSALEM, Pa.--()--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT: IMUC) securities between May 1, 2012 and December 11, 2013, inclusive (the “Class Period”). ImmunoCellular investors have until June 30, 2017 to file a lead plaintiff motion in this putative class action lawsuit.

Investors suffering losses on their ImmunoCellular investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

According to the complaint filed in this class action, starting in 2011, ImmunoCellular hired Lidingo Holdings, LLC to “pump up” the value of ImmunoCellular's stock. Allegedly, Lidingo paid people to write fake media reports that undeservedly touted ImmunoCellular stock. While the articles appeared to be unbiased and genuine on the surface, in actuality the articles were paid promotions wherein ImmunoCellular had complete editorial control of the authors' work. As a result of this deception, investors were made to believe that ImmunoCellular's studies for ICT-107 were progressing positively, leading the company's stock price to reach a high of $3.88 per share on June 1, 2012. On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against the Company, as well as other individuals and entities for engaging in unlawful stock promotion activities.

If you purchased shares of ImmunoCellular during the Class Period you may move the Court no later than June 30, 2017 to ask the Court to appoint you as lead plaintiff in this class action lawsuit if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to this lawsuit, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Recent Stories

RSS feed for Law Offices of Howard G. Smith

Release Summary

The Law Offices of Howard G. Smith Notifies Investors of the Filing of a Securities Class Action on Behalf of ImmunoCellular Therapeutics, Ltd. Investors

Law Offices of Howard G. Smith